Drug intelligence / Profile preview

2,4-diamino-6-[n-(3',4',5'-trimethoxybenzyl)-n-methylamino]pyrido[2,3-d]pyrimidine

Development stage
Unknown
Modality
Small Molecules
01

Overview

This compound is a synthetic small molecule belonging to the pyrido[2,3-d]pyrimidines class. It features a substituted pyridopyrimidine core with two amino groups at positions 2 and 4 and an N-methyl-N-(3',4',5'-trimethoxybenzyl)amino group at position 6. The compound has been cataloged in chemical and drug databases as an experimental molecule but does not have any approved medical indications or known clinical development programs. Its mechanism of action is not described in public sources; however, related pyridopyrimidine derivatives are often investigated for their potential as enzyme inhibitors or antimetabolites in cancer or antimicrobial research. No evidence suggests this specific compound has reached clinical trials or regulatory approval stages[1][2][10].

Other names
N6-methyl-N6-[(3,4,5-trimethoxyphenyl)methyl]pyrido[2,3-d]pyrimidine-2,4,6-triamine2,4-Diamino-6-(N-(3',4',5'-Trimethoxybenzyl)-N-Methylamino)Pyrido(2,3-D)Pyrimidine
02

Targets

TgDHFR-TS (Toxoplasma gondii dihydrofolate reductase-thymidylate synthase)DHFR (Dihydrofolate reductase)

Beyond the preview

Go deeper on 2,4-diamino-6-[n-(3',4',5'-trimethoxybenzyl)-n-methylamino]pyrido[2,3-d]pyrimidine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 2,4-diamino-6-[n-(3',4',5'-trimethoxybenzyl)-n-methylamino]pyrido[2,3-d]pyrimidine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call